FDA analysis has found these products to contain undeclared Furosemide, Dexamethasone and Chlorpheniramine. Furosemide was found at 5.24 mg/g or 1.84 mg/capsule. Dexamethasone was found at 2.22 mg/g or 0.780 mg/capsule. Chlorpheniramine was found at 4.38 mg/g or 1.54 mg/capsule.
Read MoreTwo new cases involving black market medicine in Texas and Tennessee, and CPB seized thousands of pills in Laredo.
Read MoreThe lawsuit against Snap may proceed and the ADA issued a statement about compounded GLP-1 medicines.
Read MoreA California man must pay millions in restitution for selling fake HIV meds. Additional news about Virginia’s state drug importation plans, prosecutions around fentanyl pills, and overseas incidents.
Read MoreA California man allegedly processed payments for foreign online pharmacies selling fentanyl and meth pills.
Read MoreNovo Nordisk filed five more lawsuits against businesses selling compounded semaglutide. Dr. Tim Mackey spoke about the dangers of the unregulated semaglutide sales online, and South Africa warned residents about counterfeit Ozempic.
Read MoreConsumption of products with undeclared sildenafil may interact with nitrates found in some prescription drugs (such as nitroglycerin) and may cause a significant drop in blood pressure that may be life threatening. People with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates. Among the adult male population, who are most likely to use this product, adult males who use nitrates for cardiac conditions are most at risk.
Read MoreUse of products with undeclared diclofenac may cause increased risk of cardiovascular events, such as heart attack and stroke, as well as serious gastrointestinal damage, including bleeding, ulceration, and fatal perforation of the stomach and intestines. This hidden drug ingredient may also interact with other medications and significantly increase the risk of adverse events, particularly when consumers use multiple NSAID-containing products.
Read MoreAnother China-based chemical company was indicted for allegedly selling precursor chemicals and xylazine to U.S. buyers as Americans continue to grapple with the toll of counterfeit prescription pills made with dangerous drugs.
Read MoreOn August 14, 2024, FDA received a complaint from a patient who noticed a black particulate in a vial of semaglutide distributed by Fullerton Wellness. On September 23, 2024, FDA received information from California regulatory authorities as part of ongoing collaboration between FDA and the state noting deficiencies found at Fullerton Wellness during a state inspection. After the state inspection, Fullerton Wellness voluntarily ceased operations.
Read More